Skip to main content

Table 4 Results of main studies of conventional treatment in AL amyloidosis

From: AL Amyloidosis

Authors (references) Regimen Year of publication and N° of patients Clonal response % (PR + CR) CR% TRM% Median survival (years)
Palladini et al. [61] M-Dex 2004/46 67 33 4 5,1
Jaccard et al. [21 M-Dex 2007/50 68 31 2 4,6
Wechalekar et al. [62] CTD 2007/75 74 21 4 3,4
Moreau et al. [63] M-Dex -Lenalidomide 2010/26 58 23 0 80% at 2 years
Kastridis et al. [64] Bortezomib + −dexamethasone 2010/94 71 25 0 76% at 1 year
Reece et al. [65] Bortezomib 2011/33 66 24 6 80% at 1 year
Mickael et al. [66] CyBorD 2012/17 94 71 0 70% at 21 months
Venner et al. [67] CVD 2012/43 81 41 0 97% at 2 years
  1. Abbreviations ; M-Dex : melphalan + dexamethasone, CTD : cyclophosphamide + thalidomide + dexamethasone, CyborD and CVD : cyclophosphamide + bortezomib + dexamethasone.